Current Report Filing (8-k)
April 30 2018 - 12:29PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act
of 1934.
Date of Report: April 25,
2018
(Date of earliest event reported)
BioVie Inc.
(Exact name of registrant as specified
in its charter)
|
|
|
|
|
Nevada
|
|
333-190635
|
|
46-2510769
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
|
|
100 Cummings Center, Suite 247-C, Beverly, MA
|
|
01915
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(312) 283-5793
(Registrant’s telephone number,
including area code)
NanoAntibiotics, Inc.
(Former Name or Former Address, if
changed since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.03 Creation of a Direct Financial Obligation.
On April 25, 2018, BioVie Inc. ("
BioVie
"
or “
Company
”) received a short-term convertible loan in the amount of $100,000 from Mr. Cuong Do, who is a member
of its Board of Directors. Under the terms of the loan, BioVie must repay the principle amount of the loan in full plus simple
interest of 10 percent not later than July 25, 2018. BioVie also has the right, instead, at any time up to and including the maturity
date of the loan, to convert the outstanding balance of the loan into BioVie stock to be issued to Mr. Do at a conversion price
of 2.5 cents per share. Alternatively, Mr. Do also has the right to require such conversion during that same period of time by
forgoing all accrued interest.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated:
April 30, 2018
|
|
|
|
BIOVIE INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Jonathan Adams
|
|
|
|
|
|
|
|
Jonathan Adams
|
|
|
|
|
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|